Other studies also found the expression of TIGIT was increased on CD56dim NK cells in CML PB while CD57 was increased on CD56dim NK cells in CML BM (179), indicating that reversing immune suppression of PB NK cells by blocking TIGIT while improving proliferation of BM NK cells via targeting CD57 may be more effective in anti-CML (Figure 3a). This evidence concerns the gene TIGIT and chronic myelogenous leukemia, BCR-ABL1 positive.